Targeting the ERK pathway in cancer cells is not simple because cells develop resistance by activating compensatory feedback loops such as the phosphatidylinositol-3-kinase (PI3K)—protein kinase B (Akt)—mammalian target of rapamycin (mTOR) (Akt/mTOR) signaling. Here, AKT1 is linked to cancer.